Bradford H N, Schmaier A H, Colman R W
Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140.
Biochem J. 1990 Aug 15;270(1):83-90. doi: 10.1042/bj2700083.
The plasma kininogens, high-molecular-mass and low-molecular-mass kininogens, are the most potent plasma inhibitors of platelet calpain. We explored the kinetic mechanisms for kininogen inhibition of calpain by comparing calpain inactivation by human high-molecular-mass kininogen (HK) and human low-molecular-mass kininogen (LK). With a [14C]methylated alpha-casein substrate, the inhibition of calpain by HK did not follow classic Michaelis-Menten kinetics. With the use of a fluorogenic assay with the dipeptide substrate for calpain, 3-carboxypropionyl-leucyltyrosine 7-(4-methyl)coumarylamide, the inhibition by HK and LK fitted a kinetic model of tight-binding inhibition. LK was found to be a non-competitive inhibitor of platelet calpain with a Ki of 2.7 nM. HK showed mixed non-competitive inhibition of calpain with a Ki of 2.3 nM in the absence of substrate and Ki of 0.71 nM in the presence of saturating substrate, almost 4-fold tighter than LK. Proteolysis of HK by plasma and tissue kallikreins did not influence its ability to inhibit calpain. Digestion of the HK light chain by Factor XIa also did not alter its calpain-inhibitory function. These studies indicate that the kininogens are tight-binding non-competitive inhibitors of platelet calpain, the inhibitory domain in each case being mainly on the heavy chain. The light chain of HK appears to influence its kinetic behaviour.
血浆激肽原,即高分子量激肽原和低分子量激肽原,是血小板钙蛋白酶最有效的血浆抑制剂。我们通过比较人高分子量激肽原(HK)和人低分子量激肽原(LK)对钙蛋白酶的失活作用,探索了激肽原抑制钙蛋白酶的动力学机制。使用[14C]甲基化α-酪蛋白底物时,HK对钙蛋白酶的抑制不遵循经典的米氏动力学。使用钙蛋白酶的二肽底物3-羧基丙酰-亮氨酰酪氨酸7-(4-甲基)香豆素酰胺进行荧光测定时,HK和LK的抑制作用符合紧密结合抑制的动力学模型。发现LK是血小板钙蛋白酶的非竞争性抑制剂,Ki为2.7 nM。HK在无底物时对钙蛋白酶表现出混合非竞争性抑制,Ki为2.3 nM,在有饱和底物时Ki为0.71 nM,比LK紧密近4倍。血浆和组织激肽释放酶对HK的蛋白水解不影响其抑制钙蛋白酶的能力。因子XIa对HK轻链的消化也未改变其钙蛋白酶抑制功能。这些研究表明,激肽原是血小板钙蛋白酶的紧密结合非竞争性抑制剂,每种情况下的抑制结构域主要位于重链上。HK的轻链似乎影响其动力学行为。